This follows post #28 rather than contradicting it.
Both are useful and different. The notice tells you the national position; the account tells you what is happening on the ground.
17 likes 22mo
Access · Shortages · continued
Second pass at: Hoarding and why it makes a shortage worse posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
I came in to disagree and I am leaving without a disagreement.
0 likes 22mo
TL4_Halvorsen, post #13: Post #10 is the version of this I will quote in future. One addition. Compounding during shortages: some jurisdictions allow pharmacy compounding when a marketed product is in shortage. That permission is jurisdiction-specific and time-limited (usually for the duration of the shortage). Small point, but it is the one that usually… Go to post
Where a shortage forces a gap, the pharmacokinetics mean a missed week is a perturbation rather than a reset, which is worth knowing.
Adding it because I spent an afternoon working it out and nobody should have to twice.
chromatogram, post #17: Manufacturer allocation decisions during a shortage are commercial and are rarely explained, which is frustrating and is not evidence of anything. A modest claim, modestly supported. Go to post
Taking post #34 at face value and following it one step further.
Shortage status determines what compounding is permitted in some jurisdictions, which links two questions that otherwise seem unrelated.
For what it is worth, the same held on the two occasions I checked.
Both are useful and different. The notice tells you the national position; the account tells you what is happening on the ground.
1 like 22mo
endo_fellow_rk, post #11: The published shortage register maintained by the national regulator is the authoritative source here, and it is updated far more often than any thread. Go to post
Compounding during shortages: some jurisdictions allow pharmacy compounding when a marketed product is in shortage. That permission is jurisdiction-specific and time-limited (usually for the duration of the shortage).
Happy to expand any of that if it is the useful part.
Collapsed as off-topic by two members at trust level 3 or above
Regional differences during a shortage are large, and a supply position in one country says nothing about another.
Worth saying I have only my own numbers here, and n is small.
c.amankwah, post #21: Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer. The conclusion is tentative; the arithmetic underneath it is not. Go to post
Anyone reporting availability should say the region and the date, because both determine whether the report is usable.
I have no interest in any supplier named above.
j.vogel, post #12: Shortage status determines what compounding is permitted in some jurisdictions, which links two questions that otherwise seem unrelated. Go to post
Picking up post #41: that is the part I would want checked first.
Shortage-driven price movement is real and is a separate question from availability.
The general answer and the answer for your case may diverge here.
Manufacturer allocation decisions during a shortage are commercial and are rarely explained, which is frustrating and is not evidence of anything.
The interesting part of this is the exception, and I do not understand the exception.
0 likes 22mo
endo_fellow_rk, post #28: Pharmacy-level availability varies enormously during a shortage, so two honest accounts from the same city can be opposite. I would rather say I do not know than round it up to an answer. Go to post
Post #43 describes the usual case. This is about the unusual one.
A shortage of one presentation is not a shortage of all of them, and the published notices are specific about which.
If that reads as pedantic, it is, and it has saved me twice.
Reports that a pharmacy has stock are the least durable information on the site and are still worth posting with a date.
A qualification I should have led with rather than closed on.
5 likes 22mo
Stockpiling in response to a shortage worsens it, which is true and is a poor argument to make to somebody who has run out.
The rule of thumb is fine; the edge cases are where it earns its keep.
0 likes 22mo
c.niemel, post #4: Taking the opening post at face value and following it one step further. Regional differences during a shortage are large, and a supply position in one country says nothing about another. I would want a second opinion before relying on that. Go to post
Supply interruptions: official shortage notices are published by regulatory agencies. That is the correct primary source rather than pharmacy rumors or forum discussion.
The arithmetic in post #50 is right; the assumption feeding it is the part to check.
Where an alternative within the class is available, the comparison is a clinical one and the doses are not equivalent.
I would want the raw data before agreeing with my own summary of it.
15 likes 22mo
chromatogram, post #17: Manufacturer allocation decisions during a shortage are commercial and are rarely explained, which is frustrating and is not evidence of anything. A modest claim, modestly supported. Go to post
Post #52 put the caveat in the right place and I want to underline it.
The published shortage register maintained by the national regulator is the authoritative source here, and it is updated far more often than any thread.
One more caveat and then I will stop qualifying: the sample selected itself.
hana.sato, post #41: Anyone reporting availability should say the region and the date, because both determine whether the report is usable. I have no interest in any supplier named above. Go to post
Anyone reporting availability should say the region and the date, because both determine whether the report is usable.
Shortage status determines what compounding is permitted in some jurisdictions, which links two questions that otherwise seem unrelated.
23 likes 22mo
I will take the caveat as seriously as the claim, which is the point of putting it there.
0 likes 22mo
Where I part company with post #56, and it is a narrow parting.
Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are different decisions.
Written in the hope of being told what I have missed.
3 likes 22mo